Season 2 (2021-2030)

Oncology - Discovery (116)

Modality Indication Targets Stage Company Project No. Detail
1 Development of Lead compound of personalized therapeutic mRNA cancer vaccine by predicting the binding of tumor.reactive T cells and neoantigens
Gene Therapy Solid Tumor Tumor specific neoantigens predicted by a GENINUS platform based on binding affinity between TCR an Hit GENINUS INC. RS-2023-00284167
2 Discovery of VRK1 inhibitor for precision medicine of advanced/ refractory solid cancer
Small Molecules Solid Tumor VRK1 Hit Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283832
3 Development of lead immunotherapy agent for cancer using IL.36 receptor agonist antibody
Antibody Melanoma IL.36 Hit Daegu Gyeongbuk Institute of Science & Technology(DGIST) RS-2023-00283446
4 IL.21 on/off switch.armored solid tumor.targeting TET KO CAR.T cell therapy
Gene Therapy Solid Tumor IL.21 Hit Seoul National University RS-2023-00282907
5 Development of tumor ECM.modifying bispecific antibody for cancer immunotherapy
Antibody TNBC, NSCLC, PC DDR1, TGF.β Hit POSTECH RS-2023-00258678
6 Development of mRNA.encoded NK cell engager for the treatment of relapsed/refractory B cell lymphoma
Nucleic acid/Virus B cell lymphoma NK cell Hit De novo Biotherapeutics RS-2023-00258675
7 Structure based drug discovery of FOXM1 inhibitor for malignant tumor therapy
Small Molecules Malignant tumor FOXM1 Hit Korea University College of Medicine RS-2022-00167112
8 Discovery of STING allosteric activator targeting non-T cell inflamed tumor
Small Molecules Solid Tumor STING Hit Korea Institute of Science and Technology RS-2022-00166522
9 Development of a new therapeutic agent for bone metastasis cancer through the development of anti-****** humanized antibody
Antibody Solid Tumor CXCL16 Hit Cellus RS-2022-00166371
10 Development of hit/lead antibody neutralizing TMPRSS4, a novel therapeutic target for the treatment of non-small cell lung cancer
Antibody NSCLC TMPRSS4 Hit Korea Research Institute of Bioscience and Biotech RS-2022-00166100
11 Development of therapeutic autologous vaccine against acute myeloid leukemia
Others AML αGC-loaded ECNV of AML Hit Seoul National University RS-2022-00165569
12 Development of macrophage-targeted clodronate-glycosylated albumin complex 
to inhibit tumor growth
Drug-conjugate Malignant tumor Macrophage Hit Seoul National University HN22C0644
13 Development of dual-functional hit/lead compounds targeting N3, a regulator of KRAS stability for the treatment of pancreatic cancer
Small Molecules Pancreatic cancer NDRG3 Hit Korea Research Institute of Bioscience and Biotech HN22C0638
14 Discovery of Translocator Protein Targeting Cancer Therapeutics as effective substances
Small Molecules Glioblastoma TSPO Hit Seoul National University HN22C0632
15 Development of tumor-derived exosome rupture peptide for combinational immunotherapy of colorectal cancer
Peptide Colorectal cancer Phopholipid layer Hit Sungkyunkwan University HN22C0624
16 Development of ALCAM aptamer-based ApDC anticancer drug
Drug-conjugate Ovary cancer ALCAM Hit HiCELL Tech HN22C0558
17 Development of CD47/CD73 dual-target SAFAbody antibody therapy for the treatment of intractable solid cancer including triple-negative breast cancer
Recombinant Protein TNBC CD47, CD73 Hit AprilBio HN22C0297
18 Discovery of novel nucleic acid-sensing pathway modulators for the TNBC treatment
Small Molecules TNBC ENPP1 Hit Korea Institute of Science and Technology HN22C0063
19 Development of complement C4d X CD3 BiTE
Antibody Cancer C4d, CD3 Hit Seoul National University HN22C0061
20 Development and optimization of a new form factor for next-generation cancer immunotherapy
Gene Therapy Solid Tumor DCs Hit Yonsei University HN21C1410
21 A study on development of lead antibodies targeting an immune checkpoint inhibitor refractory factor for metastatic melanoma
Antibody Metastatic malignant melanoma Oncokine-2 Hit Korea university HN21C0486
22 Hit and lead compound discovery of antibody-drug conjugate (ADC) targeting Doppel, a tumor-specific molecule
Drug-conjugate Cancer Doppel Hit Seoul National University HN21C0264
23 Development of lead compounds for solid tumor-targeting CC12 platform-based reinforced B7H3 CAR-T cells
Gene Therapy Solid Tumor B7-H3, IL-12 Hit Seoul National University HN21C0232
24 Development of CAR T cell safety system using chemical switch
Gene Therapy Blood Cancer CAR-DEGRON-T Hit KRICT(Korea Research Institute of Chemical Technology) HN21C0226
25 Development of antibody-based therapeutics neutralizing a novel target for the treatment of metastatic colorectal cancer
Antibody Metastatic colorectal cancer CCSP-2 Hit ASAN Medical Center HN21C0207
26 Development of ***** Targeted New Drug Lead Compounds Activating IFN-γ for Immune Checkpoint Inhibitor Resistant Cancers
Small Molecules Cancer TPST2 Hit GIST(Gwangju Institute of Science & Technology) HN21C0196
27 Development of hit and lead asymmetric anti-CD20xCD55 bispecific antibodies containing Fc variants with maximized serum half-lives and effector functions for cancer therapy
Antibody Non-Hodgkin lymphoma, CLL CD20, CD55 Hit Korea University HN21C0103
28 Development of ‘Best-in-Class’ IL-2 for Solid Tumor Treatments
Recombinant Protein Kidney cancer, Skin cancer IL-2 Hit Genuv HN21C1125
29 Development of anti-PD-L1 x anti-SIRPα bispecific antibody that systemically activates both innate and adaptive anti-tumor immune system
Antibody Solid Tumor PD-L1, SIRPα Hit PharmAbcine Inc. HN21C0973
30 Development of a CD33.targeted lead antibody for the treatment of AML based on a novel innovative antibody platform technology
Antibody Cancer CD33 Lead Centenaire Biosciences RS-2023-00283660
31 Development of SIRT7 inhibitors for the treatment of unresectable hepatocellular carcinoma
Small Molecules Cancer SIRT7 Lead Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283539
32 Novel bispecific antibodies development for Metastatic CastrationResistant Prostate Cancer
Antibody Cancer PSMA/CD137 Lead Ab Clon Inc. RS-2023-00283056
33 Development of third-generation antibody-drug conjugate linker technology capable of site-selectively conjugating payloads without antibody modification
Small Molecules Gastric/GEJ AbClickⓇPro Lead AbTis Co., Ltd. RS-2023-00259367
34 Development of small molecule targeting FoxM1 for the treatment of colorectal cancer
Small Molecules Solid Cancer FoxM1 Lead Korea Research Institute of Chemical Technology(KRICT) RS-2023-00258901
35
Small Molecules Solid Cancer TLS Lead D5 Therapeutics RS-2023-00258885
36 Development of antibody against specific target expressed in the tumor microenvironment
Antibody Cancer HGF Lead Seoul National University RS-2023-00258823
37 Development of a new Topoisomerase I inhibitor based on a Kamtotesin derivative that can be used as an ADC payload
Small Molecules Solid Tumor Topoisomerase I Lead Pinotbio, Inc. RS-2023-00258783
38 Development of a gene therapy for ovarian cancer using bispecific shRNA and antibody escaping oncolytic adenovirus
Gene Therapy Ovarian cancer c-Myc, BCL2 Lead Curigin Co., Ltd. RS-2023-00219308
39 Development of novel lead compounds inducing integrated stress response through HRI activation for the treatment of hematologic malignancies
Small Molecules polycythemia vera HRI Lead NexThera Co., Ltd. RS-2023-00218778
40 First-in-Class FLT3 Degrader Discovery Using PROTACs and Chemoproteomics
Small Molecules Acute myeloid leukemia, AML FLT3 Lead Yonsei University Industry-University Cooperation Foundation RS-2023-00218195
41 Developing Lead compound of AURKA Degrader for a potential anti-cancer therapy
Small Molecules Cancer AURKA Lead UPPthera, Inc. RS-2023-00217986
42 Generation of the lead antibody targeting APP, a novel immuno-oncology target
Antibody Solid cancer APP Lead Genome & Company RS-2023-00217717
43 Development of a lead compound for anti-cancer drug using immunoactive attenuated Salmonella
Others Solid Tumor FlaB, ClyA Lead CNCure biotech Inc. RS-2022-00167101
44 Development of a Novel Immunotherapeutics with Tumor-associated Macrophage(TAM) Suppression Mechanism
Antibody NSCLC CHI3L1 Lead Senelix RS-2022-00166446
45 Derivation of lead substance for colorectal cancer treatment of Repebody-drug conjugate with EGFR overexpression tumor-specific selective effect
Drug-conjugate Solid Tumor (EGFR overexpression) EGFR Lead ProEn Therapeutics RS-2022-00166310
46 Development of 19S RP UCHL5 inhibitors for the treatment of relapsed and refractory multiple myeloma
Small Molecules Multiple Myeloma 19S RP UCHL5 Lead Korea Research Institute of Bioscience and Biotechnology RS-2022-00166286
47 A study on the leading optimization for cancer immunotherapy of regulatory T cell suppression/depletion mechanism using CD25-ApDC (CD25 aptamer-drug-conjugate)
Drug-conjugate Solid Tumor CD25 Lead APTAMER Sciences RS-2022-00166270
48 Development of first-in-class endoglin-targeted CAR-NK and its application for inducing immune-friendly microenvironment
Gene Therapy Relapsed and Refractory Pancreatic cancer Endoglin Lead Korea Institute of Science and Technology RS-2022-00166088
49 Development for immunotherapeutics targeting tumor-associated macrophages
Antibody Solid Tumor TREM2 Lead AimedBio Inc RS-2022-00166068
50 Discovery of novel PIP5K1a inhibitors as lead compounds for mCRPC therapy
Small Molecules Prostate cancer PIP5K1α Lead TSD Life Sciences RS-2022-00165973
51 Development of a novel HPK1/MLK3 dual inhibitor, an immuno-oncology agent for MLK3-specific solid tumors
Small Molecules Brain cancer, Lung cancer HPK1/MLK3 Lead MD Biolab RS-2022-00165566
52 Development of **** inhibitor for immuno-metabolic modulator
Small Molecules Colorectal cancer GCN2 Lead 1st Biotherapeutics, Inc RS-2022-00165544
53 Discovery of novel TTK (MPS1) inhibitors for the TNBC treatment
Small Molecules TNBC TTK Lead Korea Research Institute of Chemical Technology HN22C0694
54 Development of an implantable anticancer drug for prevention of local tumor recurrence and eradication of existing metastases after tumor resection of triple-negative breast cancer(TNBC)
Drug-conjugate TNBC Nucleolin Lead Interoligo HN22C0585
55 Development of a treatment for refractory solid tumor targeting activated stellate cells
Recombinant Protein Solid tumor retinoid Lead Senelix HN22C0554
56 Discovery and development of novel ULK1 inhibitor as a therapeutic drug for RAS-mutated cancers
Small Molecules Colorectal cancer, Lung cancer, Pancreatic cancer ULK1 Lead TXINNO Bioscience Inc HN22C0244
57 Development of first-in class MASTL-targeted drug in triple-negative breast cancer
Small Molecules Breast Cancer MASTL Lead Korea Institute of Radiological & Medical Sciences HN22C0173
58 Discovery of small molecular G9a inhibitor leads in advanced solid tumor: tumor growth inhibition and anti-cancer immunity activation
Small Molecules Solid Tumor G9a Lead Asan Medical Center HN22C0033
59 Development of humanized antibody for lung cancer treatment targeting DDOST protein
Antibody Lung cancer DDOST Lead Hanyang University HN21C1351
60 Identification of leading substances for the treatment of esophageal cancer and breast cancer based on PTK7-neutralizing humanized antibodies
Antibody Esophageal squamous cell carcinoma, TNBC, PTK7 expression cancer PTK7 Lead Yonsei University HN21C1214
61 Lead Generation of DLL3-ADC for the Treatment of Small Cell Lung Cancer
Drug-conjugate Rare cancer DLL3 Lead IntoCell HN21C1082
62 A small molecule inhibitor of the ubiquitin activating enzyme for regulating p53 in lung cancer
Small Molecules Lung cancer p53 or USE1 Lead Korea Research Institute of Chemical Technology HN21C1078
63 Development of HMGCLL1 inhibitory small molecule CML therapeutic anticancer drug
Small Molecules AML, CML HMGCLL1 Lead Samsung Medical Center HN21C0954
64 Discovery of lead compounds for the development of triple negative breast cancer treatments through HDAC6/8 dual inhibition
Small Molecules TNBC HDAC6/8 Lead Sookmyung Women’s University HN21C0952
65 Tumor Targeting Liposomal Formulation of Cathepsin B-specific Doxorubicin Prodrug for Drug Resistant Cancer Treatment
Others Colerectal cancer, Breast cancer, Ovarian cancer, Pancreatic cancer Cathepsin B Lead Korea Institute of Science and Technology (KIST) HN21C0349
66 Development and optimization of lead CD5 CAR-NK for T cell malignancies
Gene Therapy Blood Cancer CD5 Lead Korea Research Institute of Bioscience and Biotechnology HN21C0117
67 Development of lead antibodies targeting an immune- checkpoint inhibitor refractory factor for metastatic non-small cell lung carcinoma
Antibody Lung cancer NSN-001 Lead NEX-I, Inc HN21C1323
68 Development of a lead compound targeting USP21 for inhibiting cancer metastasis
Small Molecules Colerectal cancer USP21 Lead Daegu Gyeongbuk Medical Innovation Foundation HN21C1210
69 Derivation of lead compound as TRIB2 inhibitor for development of triple negative breast cancer therapy
Small Molecules Breast cancer TRIB2 Lead GENESEN Co., Ltd. HN21C1201
70 Lead identification of GLS1 target via allosteric inhibition
Small Molecules Solid Tumor GLS1 Lead Korea Research Institute of Chemical Technology HN21C1180
71 Efficacy and safety on anti-cancer drug candidate of immune-checkpoint protein and cytokine fused platform
Recombinant Protein Cancer IL-21, PD-1 Lead BIOnSYSTEMS HN21C1099
72 Lead selection of PD-L1xCD3 targeted immuno-oncology (MB101) applying a novel bispecific antibody platform technology
Antibody Solid Tumor PD-L1, CD3 Lead MustBio Inc HN21C0985
73 Identification of next-generation EGFR degraders to treat Non-Small Cell Lung Cancer (NSCLC) patients
Small Molecules NSCLC EGFR mutation Lead Cyrus Therapeutics HN21C0965
74 Establishment of leading compounds to overcome tumor heterogeneity and anticancer drug resistance of pancreatic cancer and liver cancer by using oncolytic adenovirus/mesenchymal stem cell complex capable of both enhanced tumor targeting and virus replication
Gene Therapy Pancreatic cancer, Liver cancer TGFβ1, HSP27 Lead Yonsei University HN21C0960
75 GCM-101: Development of cancer-immunotherapy with oncolytic herpes simplex virus (oHSV) in ovarian cancer
Others Ovary cancer EpCAM Lead GenCellMed HN21C0935
76 Lead development study on exosomes with anticancer potential armed with FAF1, a multifunctional tumor suppressor and a genuine exosome cargo
Others Pancreatic cancer, Liver cancer FAF1 Lead ChungNam National University HN21C0048
77 Identification of small molecule PKMYT1 inhibitor candidates for development of advanced solid tumor treatment
Small Molecules Solid tumor PKMYT1 Candidate Voronoi Inc. RS-2023-00283890
78 Development of universal iPSC.NK (induced pluripotent stem cellderived NK cell therapy) with higher ability of immune evasion and persistence for the treatment of solid cancer
Gene Therapy Liver cancer IL.15RF, HLA.G Candidate Therabest Co., Ltd RS-2023-00283732
79 A Study on the Development of First.in.class Myc Inhibitor Candidate for the Treatment of Solid Tumor and Hematologic Cancer
Small Molecules Cancer Myc Candidate Incurix Co., Ltd. RS-2023-00283511
80 Development of an NMC Therapeutic Candidate Using a BRD4.NUT Degrader
Small Molecules NUT Midline Carcinoma BRD4.NUT Candidate Innocure Therapeutics Inc. RS-2023-00282701
81 Development of siRNA therapeutics to target KRAS/G12D.mutant pancreatic cancer
Gene Therapy Pancreatic cancer KRAS/G12D Candidate Exollence Co., Ltd. RS-2023-00282594
82 Development of novel small molecule anticancer drugs targeting SMARCA2
Small Molecules NSCLC, Melanoma SMARCA2/4 Candidate Hyundai Pharm RS-2023-00259457
83 The generation of candidate for Relapsed and Refractory Acute Myeloid Leukemia to FLT3 inhibitors via direct STAT5/3 inhibition
Small Molecules Acute Myeloid Leukemia STAT3/5 Candidate JW C&C Research Laboratories RS-2023-00258859
84 Direct inhibitor of AR/AR.V7 DNA binding for castration.resistant prostate cancer
Small Molecules Castration.resistant prostate cancer Androgen receptor (AR) and AR.V7 Candidate Incurix RS-2023-00258594
85 Candidate selection of a first.in.class RNA therapeuticfor the treatment of BRAF mutant pediatric brain tumors
Nucleic acid/Virus Pediatric brain tumor BRAF Candidate Sovargen RS-2023-00258484
86 Lead optimization and candidate selection of PD.L1 small molecule inhibitor for non.clinical study
Small Molecules Solid Cancer PD.1/PD.L1 Candidate Ilab RS-2023-00258167
87 Efficacy and safety evaluation of the peptide candidate CBT-001-839 for CAIX-targeted cancer diagnostic and therapeutic radiopharmaceuticals
Peptide ccRCC CAIX Candidate C-BIOMEX RS-2023-00218641
88 Derivation of First-in-Class therapeutic antibody candidate for the treatment of claudin-3 overexpressing solid cancers
Antibody CLDN3hi solid cancer CLDN3 Candidate Abion, Inc. RS-2023-00218182
89 Discovery of pre-clinical candidates for inhibition of SOS1 for the treatment of KRAS mutated cancers
Small Molecules KRAS-mutated solid cancer(Pancreatic, Lung, Colon cancer) SOS1 Candidate Jeil Pharmaceutical RS-2023-00217674
90 Candidate development of anti-TCTP neutralizing candidate (BIO101) for the treatment of solid tumors
Antibody Solid Cancer TCTP Candidate Boostimmune, Inc. RS-2023-00217478
91 Efficacy evaluation of optimized CAR-T therapy against refractory epithelial ovarian cancer
Others Ovarian cancer 메소텔린 Candidate CellenGene RS-2023-00217215
92 Development of next-generation allosteric EGFR inhibitor for non-small cell lung cancer treatment
Small Molecules NSCLC EGFR Candidate HK inno.N RS-2023-00217095
93 Development of therapeutics for acute myeloid leukemia with CK1alpha selective molecular degrader
Small Molecules AML CK1α Candidate Pin Therapeutics RS-2022-00166852
94 Development of next-generation cancer immunotherapy via FAP-targeted IL-12 attenuation-based TMEkineTM
Recombinant Protein Solid Tumor FAP, IL-12 Candidate KANAPH Therapeutics RS-2022-00166851
95 Development of HER2-positive cancer treatment candidate through interferon-beta immunocytokine efficacy evaluation and production process research
Recombinant Protein HER2+ tumor IFN-β Candidate Genopharm Inc. RS-2022-00166539
96 Candidate development of individualized cancer vaccine for the non-Hodgkin Lymphoma
Others Non-Hodgkin lymphoma Non-Hodgkin Lymphoma Candidate Progeneer RS-2022-00166284
97 Development of personalized cancer vaccine against advanced stage lung cancer patients with immunotherapy resistance
Peptide Lung cancer Tumor specific neoantigens predicted from deep learning platform technology Candidate Penta Medix RS-2022-00166187
98 Development of a non-clinical candidate for colorectal cancer treatment RACE-111 (EGFRX4-1BB) bispecific antibody
Antibody Colorectal cancer EGFR, 4-1BB Candidate CTCELLS RS-2022-00166009
99 Secured ex vivo gene therapy candidate for the treatment of solid tumor
Gene Therapy Glioblastoma Cytosine Deaminase Candidate CELL & BRAIN Co., Ltd RS-2022-00165974
100 Anti-DX2 chemical drug to control KRAS-driven cancer
Small Molecules Colorectal cancer (KRAS mutation) KRAS Candidate Zymedi HN22C0682
101 Development of a combination therapy for colorectal cancer using attenuated Salmonella and anti-PD-L1 antibody
Others Colorectal cancer Colorectal cancer (late stage) patients Candidate CNCure biotech Inc. HN22C0637
102 Polo-like kinase 1(PLK1) degradation using the N-degron pathway in PROTACs and its application of developing to non-small cell lung cancer(NSCLC) target drug candidates
Small Molecules NSCLC PLK1 Candidate DANDI CURE HN22C0563
103 ARTI 101 : Oncospreading antitumor retroviral vectors
Gene Therapy Glioblastoma Cytosine Deaminase Candidate ArtiCure HN22C0469
104 Development of immuno-cancer antibodies that improves single and/or combination anti-cancer efficacy by improving immune suppressive tumor microenvironments
Antibody Solid Tumor B7-H3/TGF-β Candidate Theranotics HN22C0442
105 Development of personalized solid cancer therapy with neoantigen targeted TCR-T cells
Gene Therapy Solid Tumor Neoantigen Candidate Neogen TC HN22C0269
106 Development of cancer cachexia treatment using anti-GFRAL antibody
Antibody Cancer Cachexia GFRAL Candidate TroyY HN22C0147
107 Development of SHP2 allosteric inhibitor with dual mechanisms of targeting the RAS pathway and enhancing anti-tumor immunity
Small Molecules Nsclc, Colerectal Cancer, Head and Neck Cancer, Esophageal Cancer SHP2 Candidate KANAPH Therapeutics HN22C0066
108 Candidate development of PD-L1xIL-2v immuno-oncology (MB201) applying a novel bispecific antibody platform technology
Antibody Solid Tumor PD-L1, IL-2 Candidate MustBio Inc HN22C0050
109 Development of anti-HLA-G/CD3 T-cell engaging bispecific antibody for the treatment of CRC patients
Antibody Colorectal cancer HLA-G, CD3 Candidate Y-Biologics HN21C1337
110 Development of peptide vaccine against the pancreatic or lung cancers with KRAS mutation
Peptide Pancreatic cancer, Lung cancer KRAS mutant Candidate NA Vaccine Institute HN21C1308
111 Identification of Preclinical Small Molecule Candidate which induces STING protein expression by inhibiting TRIM29-mediated STING Ubiquitination
Small Molecules Solid Tumor TRIM29 Candidate SPARK Biopharma, Inc. HN21C1026
112 Discovery of drug candidate for HER2 positive Breast cancer treatment using HER2 targeted Small molecule with high brain permeability
Small Molecules Breast cancer HER2 Candidate B2SBio Inc. HN21C0826
113 Novel Non-Covalent BTK Inhibitor, Exhibits Potent Anti-tumor Activity in B-Cell Lymphoma
Small Molecules CML BTK (C481S) Candidate Medytox HN21C0823
114 Development of a novel ADC for the treatment of glioblastoma
Drug-conjugate Glioblastoma FGFR3 Candidate Aimed Bio Inc. HN21C0803
115 Development of candidate compounds for 
Probe & Catch CAR-T cells targeting 
CD40-positive hematologic tumors
Gene Therapy Blood tumor CD40 Candidate TiCARos Inc HN21C0764
116 Next-generation anti-TIGIT antibody (7043H1E) with enhanced Fc function
Antibody Solid Tumor TIGIT Candidate HanAll BioPharma HN21C0596
BACK